Atorvastatin ± Aspirin in Lynch Syndrome Syndrome

Status Recruiting

Clinical Trial Summary

The goal of this study is to investigate that a common cholesterol lowering agent (atorvastatin) alone or combining with a nonsteroidal anti-inflammatory drug (aspirin) would reduce the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.

Clinical Trial Description

This is an exploratory biomarker trial to assess the ability of atorvastatin (common cholesterol lowering agent) alone or combining with aspirin (a nonsteroidal anti-inflammatory drug) to reduce the risk of colorectal cancer in high-risk individuals with Lynch Syndrome. Subjects will be stratified based on their prior history of polyps/cancer to receive atorvastatin without or with aspirin for 6 weeks. Blood and normal colon biopsies will be obtained at Day 0 and at 6 weeks on study. Tissue endpoints for analysis include cell proliferation, apoptosis and changes in gene expression. Circulating lipid profiles and metabolic function, and post-treatment questionnaires will be used to assess the acceptability of the study. ;

Study Design

Related Conditions & MeSH terms

Colorectal Neoplasms, Hereditary Nonpolyposis
Lynch Syndrome
Syndrome

Clinical Trial Details

NCT number	NCT04379999
Study type	Interventional
Source	Fox Chase Cancer Center
Contact	Yana Chertock, MA
Phone	215-214-3216
Email	yana.chertock@fccc.edu
Status	Recruiting
Phase	Early Phase 1
Start date	September 10, 2018
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT00217737` - Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer	Phase 3
Completed	`NCT00905710` - Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome	N/A
Active, not recruiting	`NCT02194387` - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members	N/A
Recruiting	`NCT04909671` - Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.	N/A
Recruiting	`NCT05692596` - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Completed	`NCT01845753` - Molecular Screening for Lynch Syndrome in Denmark
Completed	`NCT01216930` - Molecular Screening for Lynch Syndrome in Southern Denmark	N/A
Not yet recruiting	`NCT05963191` - CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome	N/A
Active, not recruiting	`NCT02912559` - Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair	Phase 3
Recruiting	`NCT04978350` - Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study	N/A
Active, not recruiting	`NCT03832985` - Pediatric Reporting of Adult-Onset Genomic Results	Early Phase 1
Withdrawn	`NCT04778566` - Evaluating the Cologuard Test for Use in Lynch Syndrome
Completed	`NCT02570516` - NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome	N/A
Completed	`NCT01823471` - I-Scan For Colon Polyp Detection In HNPCC	N/A
Recruiting	`NCT02813824` - Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome	Phase 3
Recruiting	`NCT05078866` - Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients	Phase 1/Phase 2
Recruiting	`NCT03744962` - MSI in Circulatory DNA of Endometrial Cancer
Recruiting	`NCT04711434` - PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients	Phase 3
Completed	`NCT04131062` - Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants	N/A
Recruiting	`NCT05704010` - Videocapsule Endoscopy in Lynch Syndrome	N/A